Literature DB >> 31158800

Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.

E Roos1, E C Soer2, S Klompmaker3, L L Meijer4, M G Besselink3, E Giovannetti5, M Heger1, G Kazemier6, H J Klümpen7, R B Takkenberg8, H Wilmink7, T Würdinger9, F Dijk10, T M van Gulik1, J Verheij10, M J van de Vijver11.   

Abstract

Biliary tract carcinoma (BTC) comprises gallbladder and intra-/extrahepatic cholangiocarcinoma (GBC, ICC, EHC), which are currently classified by anatomical origin. Better understanding of the mutational profile of BTCs might refine classification and improve treatment. We performed a systematic review of studies reporting on mutational profiling of BTC. We included articles reporting on whole-exome/whole-genome-sequencing (WES/WGS) and targeted sequencing (TS) of BTC, published between 2000-2017. Pooled mutation proportions were calculated, stratified by anatomical region and sequencing technique. A total of 25 studies with 1806 patients were included. Overall, TP53 was the most commonly mutated gene in BTC. GBC was associated with mutations in PFKFB3, PLXN2 and PGAP1. Mutations in IDH1, IDH2 and FGFR fusions almost exclusively occurred in ICC patients. Mutations in APC, GNAS and TGFBR2 occurred exclusively in EHC patients. In conclusion, subtypes of BTCs exhibit minor differences in mutational profile, which is likely influenced by the cell of origin.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Biliary tract; Cancer biology; Cholangiocarcinoma; Genomics

Mesh:

Substances:

Year:  2019        PMID: 31158800     DOI: 10.1016/j.critrevonc.2019.05.011

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  NUC-1031 in biliary tract cancer: from bench to bedside and back?

Authors:  Lenka N C Boyd; Godefridus J Peters; Geert Kazemier; Elisa Giovannetti
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-31       Impact factor: 3.333

Review 2.  Molecular Oncology of Gall Bladder Cancer.

Authors:  Arun Chaturvedi; Vijay Kumar; Sameer Gupta
Journal:  Indian J Surg Oncol       Date:  2019-11-16

3.  GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.

Authors:  Hongda Ding; Xixia Zhang; Yang Su; Changjun Jia; Chaoliu Dai
Journal:  Cell Mol Biol Lett       Date:  2020-02-24       Impact factor: 5.787

4.  Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR.

Authors:  Xiao Xiao; Jun Zhou; Meng Fang; Jun Ji; Chenjun Huang; Fei Du; Wenchao Ai; Ying Wang; Zhiyuang Gao; Zhiquan Qiu; Chunfang Gao
Journal:  J Clin Lab Anal       Date:  2021-11-23       Impact factor: 2.352

5.  Developing metabolic gene signatures to predict intrahepatic cholangiocarcinoma prognosis and mining a miRNA regulatory network.

Authors:  Xun Ran; Jun Luo; Chaohai Zuo; YongYe Huang; Yi Sui; JunHua Cen; Shengli Tang
Journal:  J Clin Lab Anal       Date:  2021-12-06       Impact factor: 2.352

Review 6.  Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers.

Authors:  Ruyi Zhang; Marco Puzzoni; Stefano Mariani; Yi Zheng; Nicole Liscia; Yixuan Guo; Clelia Donisi; Yu Liu; Valentino Impera; Weijia Fang; Mario Scartozzi
Journal:  Cancer Sci       Date:  2021-10-06       Impact factor: 6.716

7.  Transcriptome sequencing reveals a lncRNA-mRNA interaction network in extramammary Paget's disease.

Authors:  Da-Chao Zheng; Yan-Ting Shen; Zi-Wei Wei; Xiang Wan; Min-Kai Xie; Hai-Jun Yao; Zhong Wang
Journal:  BMC Med Genomics       Date:  2021-12-11       Impact factor: 3.063

8.  Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients.

Authors:  Giuliana Cavalloni; Caterina Peraldo-Neia; Annamaria Massa; Carlo Bergamini; Alessandro Trentini; Giovanni De Rosa; Lorenzo Daniele; Fabiola Ciccosanti; Carlo Cervellati; Francesco Leone; Massimo Aglietta
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.